Similar Posts
Development of a Multi-API (Multiparticulate) Fixed-Dose Combination Drug
Abstract: This case study provides a deep dive into Renejix’s achievement in developing a multi-API (Active Pharmaceutical Ingredient) fixed-dose combination oral drug,…
Survey Reveals Orphan Drugs Companies are Hindered by Internal Limitations
Orphan drugs encounter challenges that extend from their initial discovery to eventual launch, primarily due to the restricted patient numbers and niche…
Translating Lab Discoveries: Preclinical to First-in-Human Development.
Overview Drug developers have to take into account several factors to position a pre-clinical drug candidate successfully for first-in-human clinical trials. This executive summary will outline…
Exploring Compatibility Between Lipid-Based Formulations and Shell Materials
To ensure the physical and chemical stability of Lipid-Based Formulations (LBFs), it is essential to find a delicate balance between the formulation…
Strategies to Accelerate Your Molecule’s Development
INTRODUCTION The development of orally administered small molecules is becoming more challenging as an increasing number of molecules in pipelines have poor…
PBPK Modelling: Optimizing Controlled Release Dosage Form Development
Creating controlled release drugs, which release medicine at a specific rate or location in the digestive system, can be difficult. Physiologically-based pharmacokinetic…
